Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- EFPIA Poised to Lobby Japan on Vaccine Regulations in EPA Talks
October 22, 2015
- AMDJ to Draw Up Voluntary Rules for Managing Big Data in Field of Healthcare
October 14, 2015
- ACCJ Applauds Conclusion of TPP Talks
October 8, 2015
- EFPIA Vice President Has High Hopes for Japan’s Innovation
October 7, 2015
- EFPIA Director General Welcomes Broad Deal Reached on TPP
October 7, 2015
- JPMA President Congratulates Nobel Laureate Omura
October 7, 2015
- Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa
October 5, 2015
- New 3 Price-Band Rule Will Boost Predictability, Foster Healthy Competition: JGA Officials
October 2, 2015
- “Humanitarian Trials” Not Welcomed but Well-Designed: JPMA Regulatory Chief
September 30, 2015
- JPWA Asks LDP Bigwigs to Simplify Market Price Survey for Tax Hike If Conducted at All
September 30, 2015
- Drug Pricing Tomorrow: JMA’s Nakagawa Says Price Maintenance Premium Should Continue as Trial Measure
September 29, 2015
- April-June Generic Share at 54.4%: JGA
September 28, 2015
- Kenporen Proposal Prods Health Coverage Removal for “1st-Generation Poultices”
September 25, 2015
- JPMA Reprimands Pfizer over Failure to Report ADRs
September 18, 2015
- JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
- JPMA Policy Research Unit Sets Up Study Group on Big Data
September 10, 2015
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 2
September 8, 2015
- JPMA Chief Lauds MHLW’s Comprehensive Strategy, Says It Will Support Industry as a Whole
September 7, 2015
- JPMA to Start Educational Program for Biopharmaceutical Manufacturing Next Spring: Biopharmaceutical Chief
September 4, 2015
- Ryukaikon’s New Proposal “Will Greatly Promote the Improvement of Distribution”: JPWA President
September 2, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…